Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 8/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.54 |
| ▸ | MASP2 | O00187 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15557812 | 0.81 | BCHE (0.43) | NPY5RSCN2AJAK2 | |
| SCHEMBL4083400 | 0.80 | NQO2 (0.53) | NPY5RSCN2AHPGDSJAK2 | |
| SCHEMBL15557628 | 0.79 | KDM4E (0.44) | NPY5RJAK2 | |
| SCHEMBL15556508 | 0.79 | ALOX5 (0.44) | NPY5RJAK2 | |
| SCHEMBL1624154 | 0.78 | SCN2A (0.49) | NPY5RSCN2AHPGDS | |
| SCHEMBL15557904 | 0.77 | ALDH1A1 (0.35) | NPY5RSCN2AJAK2 | |
| SCHEMBL1630565 | 0.75 | SCN2A (0.65) | NPY5RSCN2AMASP2HPGDS | |
| SCHEMBL27756799 | 0.74 | NPY5R (0.54) | NPY5RSCN2AMASP2HPGDSJAK2 | |
| SCHEMBL31374861 | 0.74 | CYP2A6 (0.54) | — | |
| SCHEMBL13365533 | 0.74 | CYP2A6 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | claimed |
| CN-101501004-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (VG) | 2009-08-05 | — | — | CN | claimed |
| EP-2044065-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | claimed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | claimed |
| EP-2875005-B1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS INC (CN) | 2020-11-11 | — | — | EP | disclosed |
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-06-09 | — | — | US | disclosed |
| EP-2328871-B1 | HEDGEHOG PATHWAY MODULATORS | NOVARTIS AG (CH) | 2020-04-01 | — | — | EP | disclosed |
| US-9216964-B2 | Hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216964-B2 | Hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216964-B2 | Hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20150191460-A1 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2015-07-09 | — | — | US | disclosed |
| EP-2875005-A1 | N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF | Impact Therapeutics, Inc. (CN) | 2015-05-27 | — | — | EP | disclosed |
| WO-2010027746-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-11 | — | — | WO | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2009-12-17 | — | — | US | disclosed |
| CN-101501004-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (VG) | 2009-08-05 | — | — | CN | disclosed |
| EP-2044065-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008014291-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | IRM LLC (BM) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676468-B2 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | SHH, GLI1, SMO | NPY5R 3360/4885SCN2A 2991/4885MASP2 4798/4885 |
| US-20150191460-A1 | N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof | SHH, GLI1, SMO | NPY5R 3360/4885SCN2A 2991/4885MASP2 4798/4885 |
| US-20090312308-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG SIGNALING PATHWAY MODULATORS | GLI1, SHH, SMO | NPY5R 4339/4885SCN2A 1660/4885MASP2 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.